DIALOOG: Crestor in patients with diabetes mellitus type 2: lowering of LDL-C levels to new European guidelines
Study identifier:NL401017
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
DIALOOG: Crestor in patients with diabetes mellitus type 2: lowering of LDL-C levels to new European guidelines
Medical condition
Diabetes mellitus type 2, observational
Phase
-
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
2500
Study type
Observational
Age
18 Years - 70 Years
Date
Study Start Date: 01 May 2004
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Astra Zeneca
AstraZeneca
